Boryung actively pursues co-promotion deals…

‘entering new market·expanding external growth‘

This year, Boryung signed co-promotion agreements with Baxter·Healcerion·Bixink

Boryung proactively engaged in collaboration after signing a joint-distribution agreement for the 'K-CAB-Kanarb series' at the end of last year

The company is aiming to achieve synergy via external growth, expanding its portfolio, and entering a vulnerable market

Boryung proactively seeks opportunities to partner with pharmaceutical and biotechnology companies in South Korea and overseas.

 

Boryung appears to be in full swing after signing a co-distribution agreement with HK inno.N for 'K-CAB' and the four items of 'Kanarb' series at the end of last year.

 

Pharmaceutical industry experts anticipate that Boryung could achieve synergy, including external growth, portfolio expansion, and strengthening its capacity in a vulnerable market, through a co-promotion expansion strategy.

 

Joint distribution of breast cancer treatment 'Nerlynx'…Boryung strengthens its anticancer therapy portfolio Boryung reported on April 9 that it signed a mutual co-promotion agreement with Bixink Therapeutics for two types of breast cancer treatment.

 

According to the agreements, they will begin jointly selling and marketing Bixink Therapeutics’ 'Nerlynx (neratinib)' and Boryung’s 'Fulvet (fulvestrant).' Nerlynx is an oral HER2-positive breast cancer treatment.

 

It was approved by the U.S.

 

Food and Drug Administration (FDA) in 2017, and Bixink Therapeutics introduced the drug in South Korea in 2021.

 

Nerlynx is the only extended adjuvant therapy available in South Korea, designed to lower the risk of HER2-positive early-stage breast cancer recurrence and prevent brain metastasis.

 

Fulvet is a generic version of Faslodex that was launched by Boryung last year.

 

It is used either alone or as a combination therapy to treat patients with hormone receptor-positive or HER2-negative, post-menopause progressive·metastatic breast cancer.

 

Boryung expands its portfolio.

The current agreement is expected to provide a synergy to both companies.

 

Bixink Therapeutics can expect to strengthen its sales and marketing capacity, while Boryung can expect to expand its product portfolio.

 

Boryung has added new anticancer drugs, 'Xeloda'·'Taxol'·'Samfenet,' to its portfolio.

 

According to IQVIA, a pharmaceutical market research agency, Nerlynx generated KRW 8.2 billion in sales last year, an increase of sevenfold compared to KRW 1.2 billion in 2022, when it first launched.

 

With Boryung’s sales capacity, the drug’s annual sales can be expected to surpass KRW 10 billion.

 

This year, the company has signed several co-promotion deals for 'Sonon 500L'·'Suprane Solution'·'Plasma Lyte' On March 21, Boryung has signed a co-promotion agreement with Healcerion for the portable ultrasound device 'Sonon 500L.' Since the beginning of this month, Boryung has been distributing Sonon 500L to nephrology clinics nationwide.

 

The Sonon 500L is a wireless ultrasound device developed by Healcerion for clinical diagnosis.

 

It is convenient and economically affordable compared to bulky conventional wired ultrasound machines.

 

This product assists in locating blood vessel positions during blood dialysis.

 

Dialysis patients need to insert a needle into their blood vessels three times a week for dialysis.

 

However, the lack of nephrology dialysis rooms equipped with ultrasound machines has caused inconvenience in this process.

 

Through the Sonon 500L co-promotion, Boryung expects to strengthen its position in nephrology.

 

Boryung is the only domestic pharmaceutical company operating a specialized dialysis agency that supplies products related to kidney disease treatment.

 

By adding an ultrasound device targeting dialysis rooms, synergy with existing nephrology-related products is anticipated.

 

Boryung’s CEO Duhyeon Chang (left) and Healcerion’s CEO Jeong-won Ryu (right).

In January of this year, Boryung signed a domestic sales agreement with Baxter for the inhaled anesthetic 'Suprane Solution' and the IV infusion 'Plasma Lyte.' Suprane Solution is a conventional inhaled anesthetic used for inducing and maintaining anesthesia during surgeries.

 

Plasma Lyte is an IV infusion developed by Baxter.

 

It is used to supply and correct extracellular fluid when the circulating blood volume or interstitial fluid is reduced.

 

Through this agreement, Boryung expanded its portfolio of drugs used for anesthesia.

 

Boryung previously sold the antiemetic 'Naseron (ramosetron)' and the reversal agent of muscle relaxant 'Breathon (sugammadex).' On April 3, Boryung signed a memorandum of understanding (MOU) with Vivozon Pharmaceutical to commercialize the non-narcotic analgesic Unafra (opiranserin) in South Korea.

 

Opiranserin is a non-narcotic analgesic used for postoperative pain, and domestic product approval is expected by the end of the year.

 

Upon receiving product approval, Vivozon Pharmaceutical will supply finished products to Boryung, and both companies will be responsible for distribution and sales, respectively.

 

Boryung started to strengthen its partnership after signing a co-distribution agreement for its 'K-CAB'-'Kanarb' series last year Boryung appears to be in full swing for expanding partnership after signing a co-distribution agreement with HK inno.N for 'K-CAB'-'Kanarb' series at the end of last year.

 

In December of last year, Boryung partnered with HK inno.N to jointly sell 'K-CAB' and four items of the 'Kanarb' series (Kanarb·Dukaro·Dukarb·Dukarb Plus).

 

These two items are both blockbuster drugs with annual sales of over KRW 100 billion.

 

HK inno.N’s CEO Dalwon Kwak (left), Boryung’s CEO Duhyeon Chang (right).

Pharmaceutical industry experts anticipate that Boryung’s proactive expansion through partnerships will bring positive effects, including increased external growth, portfolio diversification, and entry into new markets.

 

Boryung has set a sales target of 1 trillion won for this year.

 

Last year, Boryung recorded sales of KRW 859.6 billion.

 

Mathematically, sales need to increase by more than KRW 140 billion compared to the previous year, and it is expected that the contribution of K-CAB will likely play a significant role in this.

 

In addition, it is also likely that the products covered by the co-promotion agreement signed this year will contribute to achieving this goal.

 

By adding Nerlynx to their anticancer portfolio, Boryung can anticipate portfolio expansion, building on past strengths.

 

Additionally, the company can now aim to strengthen its position in areas such as gastroenterology, nephrology, and anesthesiology, where its marketing and sales capabilities have been analyzed as lacking.

 

The K-CAB co-promotion is expected to significantly boost Boryung's marketing and sales capabilities in the gastroenterology field.

 

“We will create momentum for sustained growth through mutual co-promotion with diverse companies.

 

We will also seek opportunities for mutual growth by establishing a 'collaborative business model,' which has been difficult to find in the industry,” the official from Boryung stated.